Robin A Fairhurst

5PUBLICATIONS
10CO-AUTHORS
Biomolecular modelling and designMolecular targetsHaematological tumoursCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 02, 2026
Multi-objective optimization in the context of generative chemistry.

|May 02, 2022
Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

Robin A Fairhurst, Pascal Furet, Patricia Imbach-Weese

|Sep 15, 2020
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.

Robin A Fairhurst, Thomas Knoepfel, Nicole Buschmann

|Aug 15, 2019
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.

Andreas Weiss, Flavia Adler, Alexandra Buhles

|Aug 16, 2018
Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

Robin A Fairhurst, Thomas Knoepfel, Catherine Leblanc

Pageof 1

Frequent Collaborators

2 joint publications

Thomas Knoepfel

1 joint publications

William R Sellers

1 joint publications

Wolfgang Jahnke

1 joint publications

Frédéric Stauffer